Gilead Sciences, Inc. (GILD) income statement
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/3099% above fair value
$166.43−0.10 (-0.06%)
Close on Nov 20, 2026Market cap $206.43BP/E –Yield 1.90%
Gilead Sciences, Inc. financial ratios
See a number that looks wrong?